VitaDAO has raised $4.5M across 2 funding rounds.
Key people at VitaDAO.
VitaDAO has raised $4.5M in total across 2 funding rounds.
VitaDAO has raised $4.5M in total across 2 funding rounds.
VitaDAO's investors include Pfizer Venture Investments, 2xN, Andreessen Horowitz, Angel investor, Catalio Capital, Haun Ventures, Highbury Group, Ulu Ventures, What If Ventures, WndrCo LLC.
VitaDAO is a decentralized collective that funds early-stage longevity and aging research using blockchain-based governance and funding mechanisms. Its mission is to extend human healthspan and lifespan by researching, financing, and commercializing longevity therapeutics in an open, democratic, and community-driven manner. VitaDAO pools resources from a global community of scientists, blockchain enthusiasts, and longevity experts to support innovative, high-risk, high-reward projects that traditional funding often overlooks. It serves researchers, startups, and the broader longevity ecosystem by accelerating the translation of aging science into commercial biotech ventures, having already funded over two dozen projects and spun out companies like VitaFirst and ArtanBIO[1][2][3][4].
Founded around 2021, VitaDAO emerged from the convergence of blockchain technology and longevity science, aiming to democratize funding for aging research. Key founding members include longevity advocate and investor Laurence Ion, who envisioned a platform where anyone could participate in funding and decision-making through decentralized governance. The idea arose from the need to overcome traditional barriers in longevity research such as funding scarcity, regulatory hurdles, and lack of transparency. Early traction included raising millions in capital and successfully incubating projects that spun out into independent ventures, demonstrating the viability of a community-governed research funding model[2][3].
VitaDAO rides the wave of decentralized finance (DeFi), Web3, and community-driven innovation intersecting with the rapidly growing longevity biotech sector. The timing is critical as aging research is gaining momentum due to advances in biology, AI, and increasing public interest in healthspan extension. By democratizing funding and IP ownership, VitaDAO challenges traditional pharma R&D models, promoting transparency, collaboration, and faster translation of science to therapies. This approach aligns with broader trends toward open science, decentralized governance, and tokenized assets, potentially reshaping how biomedical innovation is financed and governed[3][4][6].
Looking ahead, VitaDAO aims to expand its community and funding capacity, further integrating AI to accelerate research and discovery. The longevity field’s growth, combined with increasing acceptance of decentralized governance models, positions VitaDAO to become a key player in funding and commercializing next-generation therapeutics. Its influence may extend beyond longevity, serving as a blueprint for decentralized, community-driven science funding in other domains. The challenge will be scaling governance, maintaining scientific rigor, and successfully commercializing funded projects to sustain the DAO’s ecosystem and impact[2][4][6]. Ultimately, VitaDAO exemplifies a pioneering fusion of blockchain and biotech to make aging a modifiable condition rather than an inevitable decline.
Key people at VitaDAO.
VitaDAO has raised $4.5M across 2 funding rounds. Most recently, it raised $4.0M Seed in January 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2023 | $4.0M Seed | Pfizer Venture Investments | |
| Aug 1, 2022 | $500K Seed | 2xN, Andreessen Horowitz, Angel investor, Catalio Capital, Haun Ventures, Highbury Group, Pfizer Venture Investments, Ulu Ventures, What If Ventures, WndrCo LLC |
